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ABSTRACT 
The aim of present investigation was to develop press coated tablets for Floating pulsatile drug delivery of Ivabradine used for is a medication 
used for the symptomatic management of stable heart-related chest pain and heart failure not fully managed by beta blockers. The drug 
delivery system was designed to deliver the drug such a time when it could be needful of patient conditions. The press coated tablets containing 
Ivabradine in the inner core were formulated by direct compression method with an outer coating of different amount of HPMCK200 M. The 
release profile of press coated tablet exhibited a lag time. The optimized batch F9 gave good drug release of 99.58 %. 
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In recent years, a major goal for the drug delivery research 
is turned towards the development of efficacious drug 
delivery systems with already existing active ingredients in 
case of new drug discovery.  Many of pharmaceutical 
therapeutic agents are mostly effective when made 
available at constant rates or near to absorption sites. 
Much effort has  been  going  on  to  develop  sophisticated  
drug  delivery  systems  such  as  osmotic devices  for  oral  
application.  Oral  drug  delivery  system  is  more  favored  
on  popular controlled drug delivery system in 
pharmaceutical research and development (R&D) business 
due to increase in awareness of medical and 
pharmaceutical community about the importance of safe 
and effective use of drug. This system aims to maintain 
plasma drug concentration within the therapeutic window 
for long period of time.1 
2. MATERIALS AND METHODS 
Materials: Ivabradine was obtained as a gift sample from 
Biocon Limited., Crospovidone, Sodium starch glycolate, 
Croscarmellose sodium and Sodium carbonate was obtained 
from Yarrow chem products. Mumbai, Avicel-PH102, 
Magnesium stearate, Talc, Lactose was purchased from 
Signet chemicals, Mumbai. 
 
Methods: 
2.1. Analytical method development: 
a) Preparation of calibration curve in 0.1N HCL: 
10mg of Ivabradine pure drug was dissolved in 10ml of 
methanol (stock solution 1). 1ml of solution was taken and 
make up with10ml of 0.1N HCL (100μg/ml) stock-2. From 
this 1ml was taken and make up with 10 ml of 0.1N HCL 
(10μg/ml) stock-3. The above stock-II solution was 
subsequently diluted with 0.1N HCL to obtain series of 
dilutions containing and 2,4,6,8 and 10μg/ml of solution. The 
absorbance of the above dilutions was measured at 286 nm 
for 0.1N HCL by using UV-Spectrophotometer taking 0.1N 
HCL as blank. Then a graph was plotted by taking 
Concentration on X-Axis and Absorbance on  Y-Axis which 
gives a straight line Linearity of standard curve was assessed 
from the square of correlation coefficient (R2) which 
determined by least-square linear regression analysis.  
Preparation calibration curve in pH 6.8 phosphate buffer:  
10mg of Ivabradine pure drug was dissolved in 10ml of 
methanol (stock solution 1). 1ml of solution was taken and 
make up with10ml of 6.8 Phosphate buffer (100μg/ml) i.e. 
stock-2. From this 1ml was taken and make up with 10 ml of 
6.8 Phosphate buffer (10μg/ml) i.e. stock-3. The above stock-
II solution was subsequently diluted with 6.8 Phosphate 
buffer to obtain series of dilutions Containing and2, 4, 6, 8 
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and 10μg/ml of solution. The absorbance of the above 
dilutions was measured at 286 nm for 6.8 Phosphate buffer 
by using UV-Spectrophotometer taking 6.8 Phosphate buffer 
as blank. Then a graph was plotted by taking Concentration 
on X-Axis and Absorbance on  Y-Axis which gives a straight 
line Linearity of standard curve was assessed from the square 
of correlation coefficient (R2) which determined by least-
square linear regression analysis.    
2.2. Drug – Excipient compatibility studies: 2-5  
Fourier Transform Infrared (FTIR) spectroscopy: 
The compatibility between the pure drug and excipients was 
detected by FTIR spectra obtained on Bruker FTIR Germany 
(Alpha T). The solid powder sample directly place on yellow 
crystal which was made up of ZnSe. The spectra were 
recorded over the wave number of 4000 cm-1 to 550 cm-1. 
2.3. Formulation development of Tablets: 6-15 
Formulation of core tablets by direct compression:  
The inner core tablets were prepared by using direct 
compression method. Powder mixtures of Ivabradine, 
microcrystalline cellulose, CCS, Talc, ingredients were dry 
blended for 20 min. followed by addition of Magnesium 
Stearate. The mixtures were then further blended for 10 
min., 60mg of resultant powder blend was manually 
compressed using, Lab press Limited, India with a 6mm 
punch and die to obtain the core tablet.  
  
Formulation of mixed blend for barrier layer:  
The various formulation compositions containing Eudragit S-
100, Ethyl cellulose, HPMC-K200M, Magnesium stearate, talc 
and Microcrystalline cellulose. Different compositions were 
weighed dry blended at about 10 min. and used as press 
coating material to prepare press-coated pulsatile tablets 
respectively by direct compression method. 
Preparation of press-coated tablets:  
The core tablets were press-coated with 120 mg of mixed 
blend. 100 mg of barrier layer material was weighed and 
transferred into a 7mm die then the core tablet was placed 
manually at the center. The remaining of the barrier layer 
materiel was added into the die and compressed by using 
Lab press Limited, India. 
Table 1: Formulation development of core tablets 
Ingredients C1 C2 C3 
Ivabradine 5 5 5 
Croscarmellose sodium 10 15 20 
Microcrystalline cellulose 26 21 16 
PVP k 30 15 15 15 
Magnesium stearate 3 3 3 
Talc 1 1 1 
Total weight 60 60 60 
 
Table 2:  Formulations for press coated tablets 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Eudragit S-100 10 20 30 -- -- -- -- -- -- 
Ethyl Celluose (EC) -- -- -- 10 20 30 -- -- -- 
HPMC K200M -- -- -- -- -- -- 10 20 30 
PVP K30 15 15 15 15 15 15 15 15 15 
Sodium bicarbonate 10 10 10 10 10 10 10 10 10 
Magnesium Stearate 3 3 3 3 3 3 3 3 3 
Microcrystalline 
cellulose 
81 71 61 81 71 61 81 71 61 
Talc 1 1 1 1 1 1 1 1 1 
Total weight (mg) 120 120 120 120 120 120 120 120 120 
 
3. RESULTS AND DISCUSSION 
Present study was done on pulsatile tablets with different 
formulations F1 to F9. Formulations had weight ratio of 
polymers like Eudragit S-100, Ethyl cellulose, HPMC K200M 
along with various excipients. Ethyl cellulose is an 
insoluble.  
 
3.1 Preformulation Studies: 
Standard graph of Ivabradine in 0.1N HCL: 
Ivabradine showed maximum absorbance in 0.1N HCL 
at 286 nm.  The solution obeyed Beer-Lambert’s law for 
concentration range of 0μg/mL to 10μg/mL with regression 
coefficient of 0.998. Standard curve of Ivabradine prepared 




Table 3: Calibration data of Ivabradine in 0.1N HCL 









Fig. 1: Standard Graph of Ivabradine in 0.1N HCL
 
y = 0.094x - 0.021 
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3.2:  FT-IR (Fourier Transform Infrared Spectrophotometry) 
 
Fig. 2:  FTIR spectra of Ivabradine pure drug 
 
Fig. 3: FTIR spectra of Optimized Formula 
 
The spectra for pure Ivabradine and for the physical mixture 
of Ivabradine and all the polymers were determined to check 
the intactness of the drug in the polymer mixture using FTIR 
Spectrophotometer.  
The comparative FTIR studies of Drug and excipients 
combination had shown negligible variation in the values as 
compared with that of only pure form of Drug. Therefore it 
implies good compatibility of drug and excipients. 
From the above table, the wave number of mixture of drug 
with excipients is within the range of wave number of pure 
drug. This implies that the excipients are compatible with 
the drug since their combination did not alter the functional 
groups of pure drug 
 




Angle of repose (
o





Carr’s index (%) Hausner’s Ratio 
C1 26.29 0.34 0.38 10.52 1.11 
C2 27.29 0.33 0.38 13.15 1.15 
C3 28.29 0.34 0.38 13.14 1.14 
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Tablet powder blend was subjected to various pre 
formulation parameters. The angle of repose values indicates 
that the powder blend has good flow properties. The bulk 
density of all the formulations was found to be in the range 
of   0.33 to 0.34 (gm/cm3) showing that the powder has good 
flow properties. The tapped density of all the formulations 
was found to be in the range of 0.38 showing the powder has 
good flow properties. The compressibility index of all the 
formulations was found to be ranging from 10.52 to 13.15 
which were showed that the powder has good flow 
properties. All the formulations has shown the hausner ratio 
ranging from  0 to 1.15 indicating the powder has good flow 
properties. 
 
















C1 59.12 1.13 0.24 0.345 98.18 15 
C2 60.28 1.25 0.18 0.287 99.27 10 
C3 60.77 1.34 0.22 0.321 99.13 18 
 
All the parameters such as weight variation, friability, 
hardness, thickness and drug content were found to be within 
limits. 
Weight variation and thickness: All the formulations were 
evaluated for uniformity of weight using electronic weighing 
balance. The average tablet weight of all the formulations 
was found to be between 9.12 to 60.77. The maximum 
allowed percentage weight variation for tablets weighing 
<80 mg is 10% and no formulations are not exceeding this 
limit. Thus all the formulations were found to comply with 
the standards given in I.P. And thickness of all the 
formulations was also complying with the standards that 
were found to be between 0.287 to 0.345. 
Hardness and friability:  
All the formulations were evaluated for their hardness, using 
monsanto hardness tester. The average hardness for all the 
formulations was found to be between (1.13– 1.34) Kg/cm2 
which was found to be acceptable.  
Friability was determined to estimate the ability of the 
tablets to withstand the abrasion during packing, handling 
and transporting. All the formulations were evaluated for 
their percentage friability using Roche friabilator. The 
average percentage friability for all the formulations was 
between 0.18-0.24 which was found to be within the limit. 
Drug content: The drug content values for all the 
formulations were found to be in the range of 98.18 to 99.27. 
According to IP standards the tablets must contain not less 
than 95% and not more than 105% of the stated amount of 
the drug. Thus, all the formulations comply with the 
standards given in IP. 
In-vitro disintegrating time: The in vitro disintegration 
time values for all the formulations were found to be in the 
range of 10 to 18 mins. 
 
Table 6: Pre compression Parameters of Ivabradine coated Tablets 
 
Formulation code Angle of repose (
o






F1 17.10 0.318 0.38 16.31 1.19 
F2 28.97 0.342 0.4 15.0 1.17 
F3 18.19 0.34 0.43 20.93 1.26 
F4 22.61 0.36 0.42 14.28 1.16 




23.10 0.33 0.42 22.35 1.28 
F7 19.85 0.33 0.41 19.51 1.24 
F8 21.80 0.32 0.42 24.70 1.32 
F9 17.74 0.33 0.4 17.5 1.21 
 
Tablet powder blend was subjected to various pre 
formulation parameters. The angle of repose values indicates 
that the powder blend has good flow properties. The bulk 
density of all the formulations was found to be in the range 
of 0.32 – 0.342 (gm/cm3) showing that the powder has good 
flow properties. The tapped density of all the formulations 
was found to be in the range of 0.38 - 0.43 showing the 
powder has good flow properties. The compressibility index 
of all the formulations was found to be ranging from 14 to 24 
which show that the powder has good flow properties. All 
the formulations has shown the hausner ratio ranging 
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F1 178.28±0.12 5.82±0.22   2.12±0.78 0.54±0.28 99.28 3.2 5 
F2 180.03±0.95 5.66±0.51 2.67±0.64 0.23±0.34 98.12 3.4 10 
F3 176.98±0.74 5.09±0.95 1.85±0.48 0.47±0.94 99.73 3.8 12 
F4 180.57±0.64 5.16±0.46 2.45±0.32 0.61±0.47 100.01 3.1 5 
F5 179.48±0.37 5.77±0.37 1.98±0.17 0.44±0.85 97.42 3.6 10 
F6 178.61±0.56 5.62±0.55 2.12±0.95 0.50±0.24 99.35 3.2 12 
F7 176.38±0.33 5.94±0.48 2.44±0.81 0.38±0.95 98.75 2.6 8 
F8 177.73±0.76 5.81±0.72 2.89±0.99 0.31±0.81 99.41 2.0 11 
F9 180.05±0.84 5.19±0.22 3.18±0.75 0.55±0.76 99.27 3.4 12 
 
In-Vitro Drug Release Studies of Ivabradine core tablet: 
In vitro dissolution studies of Ivabradine core tablets 
were performed using USP XXIII Type II rotating paddle 
dissolution apparatus  by using phosphate buffer (pH 6.8) 
as a dissolution medium. From formulation C1-C3 
Ivabradine core tablets, C2 showed faster drug release 
than the other formulations. Faster drug release can be 
correlated with the high disintegration time. So, C2 
formulation was selected as best formulation for further 
press coating and enteric coating formulations.   
Table 8: Drug release of Ivabradine core tablets 
Time (min) C1 C2 C3 
0 0 0 0 
5 12.82 18.98 7.98 
10 22.08 35.48 10.14 
15 37.41 55.58 36.98 
20 67.66 82.31 58.9 
30 91.2 96.88 92.53 
45 94.6 98.86 96.66 
60 96.92 99.76 98.27 
 
 
Fig. 4: Cumulative % drug released of 
Ivabradine core tablets 
In vitro drug release study of Ivabradine pulsatile 
tablets: 
 The time dependent pulsatile tablets were prepared by using 
different concentrations of Eudragit S-100. The formulation C2 
showed maximum drug release at immediately. So, C2 
formulation was selected as best formulation for further 
press coating and enteric coating formulations. 
Table 9: Cumulative % drug Release of Coated 
Ivabradine Tablets containing Eudragit S-100 
Time (hr) F1 F2 F3 
0 0 0 0 
0.5 0.14 0.13 0.12 
1 0.18 0.19 0.22 
2 0.25 0.21 5.43 
3 28.54 25.29 15.68 
4 50.34 30.18 24.32 
5 98.37 41.72 30.62 
6 --- 51.31 39.57 
7 --- 60.34 44.28 
8 --- 72.48 50.02 
9 --- 88.68 61.25 
10 --- 100.64 77.31 
11 --- --- 84.92 
12 --- --- 95.45 
 
 
Fig. 5: Cumulative % drug release study of Ivabradine 
pulsatile tablets (F1, F2 & F3) 
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Table 10: Cumulative % drug Release of Coated 
Ivabradine Tablets containing Ethyl cellulose 
Time (Hrs) F4 F5 F6 
0 0 0 0 
0.5 0.28 0.12 0.11 
1 12.56 0.19 0.17 
2 28.18 1.95 1.35 
3 50.34 10.12 9.38 
4 85.17 21.23 20.38 
5 90.61 30.22 28.39 
6 99.76 39.15 35.59 
7 --- 43.52 40.38 
8 --- 49.06 52.12 
9 --- 55.79 64.21 
10 --- 75.34 74.86 
11 --- 94.25 80.67 
12 --- --- 94.76 
                                     
 
Fig. 6: Cumulative % drug release study of Ivabradine 
pulsatile tablets (F4, F5 & F6 
Table 11: Cumulative % drug Release of Coated 
Ivabradine Tablets containing HPMC K200M 
Time (Hrs) F7 F8 F9 
0 0 0 0 
0.5 0.19 0.16 0.12 
1 0.65 0.54 0.54 
2 1.95 1.84 0.59 
3 5.39 14.74 19.74 
4 13.73 20.38 25.38 
5 27.37 38.48 36.48 
6 41.38 47.48 45.48 
7 63.83 50.29 52.29 
8 80.29 61.27 66.27 
9 96.38 79.38 71.38 
10   ---  86.39 78.39 
11  --- 96.28 86.28 
12  --- ---  99.58 
                   
 
Fig. 7: Cumulative % drug release study of Ivabradine 
pulsatile tablets (F7, F8, F9) 
4. CONCLUSION 
Ivabradine Pulsatile dosage form was formulated by press 
coating technique. The lag time and time controlled release 
behavior of Ivabradine from press coated tablets could be 
modulated by varying the concentration of polymer in outer 
coating layer and thickness if compression coating.  From 
formulation C1-C3 Ivabradine core tablets, C2 showed 
faster drug release than the other formulations. Faster 
drug release can be correlated with the less 
disintegration time. So, C2 formulation was selected as best 
formulation for further press coating and enteric coating 
formulations. Among All Formulations F9 was showed 
maximum % drug release 99.58% at 12 hours. Hence F9 
Formulation was considered as optimized Formulation. 
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